

SUBJECT INDEX VOLUME 17

A

- ACTH
 ipsapirone, 382
- Adenosine receptors
 antipsychotic effects, 82
- Adrenocorticotropic hormone (ACTH). See ACTH
- Affective instability
 physostigmine effects, 264
- Alpha-methyl-para-tyrosine (AMPT)
 dopamine effects, 162
- Amperozide
 effects, 197
- Amphetamines
 adenosine A_{2A} agonists, 82
 chronic pretreatment effects, 130
- AMPT
 dopamine effects, 162
- Amygdala
 neuropeptide Y electrophysiologic actions, 34
- Anticipation
 schizophrenia, 279
- Antidepressant response
 sleep deprivation effects on serotonin, 72
- Antidepressants
 m-Chlorophenylpiperazine, 341
 clinical trials, 110, 113
 fluoxetine effects on sleep EEG, 241
 response time, 110, 113
 tricyclic effects, 1
- Antiglucocorticoids
 effects on 5-HT_{1A} function, 246
- Antipsychotics
 adenosine A_{2A} agonists, 82
 amperozide, 197
 effects on regional cerebral blood flow, 230
 MDL 100,907
 positron emission tomography (PET) study, 175
 upregulation of D₂-like receptor subtypes, 186
- Anxiety disorders
 cholecystokinin (CCK), 360
- AP-1 transcription factor
 lithium effects, 12
- Aporphines
 upregulation of D₂-like receptor subtypes, 186
- Arginine vasopressin
 major depression, 284
- AtT-20 pituitary cells
 IL-2 receptor-β cDNA clones, 57
- Attention
 dextroamphetamine effects on brain glucose metabolism, 370
- Autoradiography
 upregulation of D₂-like receptor subtypes, 186

B

Behavioral depression

- chronic amphetamine pretreatment effects, 130
- Behavioral sensitization
 chronic amphetamine pretreatment effects, 130
 schizophrenia, 205
- Benzodiazepines
 premenstrual syndrome, 370
- Bipolar disorder
 lithium effects, 12
- Borderline personality disorder
 cholinergic agents, 264
- Brain
 upregulation of D₂-like receptor subtypes, 186
- Brain glucose metabolism
 dextroamphetamine, 370
- Brain imaging
 neuropsychiatric disorders, 293
- Brain radionuclide imaging
 cocaine withdrawal and striatal 6-FDOPA uptake, 401

C

- C-Fos expression
 nicotine effects, 151
- c-Fos immunohistochemistry
 Y-43611 effects, 27
- Calcium
 protein kinase C (PKC) activation, 117
- Catalepsy
 adenosine A_{2A} agonists, 82
- Cerebral blood flow
 regional
 antipsychotics effects, 230
- Children
 fluoxetine effects on sleep EEG, 241
 m-Chlorophenylpiperazine depression, 341
- Cholecystokinin (CCK)
 anxiety disorders, 360
- Cholinergic agents
 borderline personality disorder, 264
- Chromosome 6
 schizophrenia, 279
- Clozapine
 schizophrenia, 316
 upregulation of D₂-like receptor subtypes, 186
- Cocaine
 withdrawal and striatal 6-FDOPA uptake, 402
- Cognition
 ketamine effects, 141
 phencyclidine effects, 92
- Conditioned place preference paradigm
 oxytocin, 353
- Corticotropin-releasing factor
 autoradiographic localization in rat brain, 307
 distribution of axons across human brainstem nuclei, 325
 lithium effects, 12
- Cortisol

- fluoxetine effects, 1
 ipsapirone, 382
 major depression, 284
 menstrual cycle, 100
- Cyclic AMP responsive element. See CRE

D

- Depression
 antiglucocorticoids effects on 5-HT_{1A} function, 246
 arginine vasopressin, 284
 behavioral
 chronic amphetamine pretreatment effects, 130
 fluoxetine effects, 1
 fluoxetine effects on sleep EEG, 241
 sleep deprivation effects on serotonin, 72
 sumatriptan effects on serotonergic function, 258
 tryptophan depletion, 341
- Desensitization
 regulation of 5-HT_{1A} receptor variants, 18
- Dexamethasone
 menstrual cycle, 100
- Divalproex sodium
 effects on 5-HT_{1A} receptor function, 382
- Dopa analogs and derivatives
 cocaine withdrawal and striatal 6-FDOPA uptake, 402
- Dopamine
 amperozide effects, 197
 dopamine D₂ receptor occupancy, 162
 phencyclidine effects, 92
 schizophrenia, 205
- Dopamine D₂ receptors
 nafadotride effects, 67
 occupancy by exogenous dopamine, 162
- Dopamine D₃ receptors
 effects on gene expression in rat forebrain, 27
- Dopamine D₄ receptors
 effects on gene expression in rat forebrain, 27
- Dopamine D₂-like receptors
 effects on gene expression in rat forebrain, 27
- Dopamine metabolism
 cocaine withdrawal and striatal 6-FDOPA uptake, 402
- Dopamine receptors
 upregulation of D₂-like receptor subtypes, 186
- Dorsal hippocampus
 neuropeptide Y electrophysiologic actions, 34
- Dorsal raphe nucleus
 risperidone effects, 44
 sleep deprivation effects on serotonin, 72
- Down-regulation
 regulation of 5-HT_{1A} receptor variants, 18
- Drug abuse
 glycine modulation of phencyclidine (PCP)-induced activity, 202
- Drug withdrawal

- chronic amphetamine pretreatment effects, 130
- Dysphoria
borderline personality disorder, 264
- E**
- EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinolone)
nafadotride effects, 67
- EEG
neuropeptide Y electrophysiologic actions, 34
sleep
fluoxetine effects, 241
- Electroencephalography (EEG). See EEG
- Electrophysiology
risperidone effects, 44
- ERPs
neuropeptide Y electrophysiologic actions, 34
- Event-related potentials (ERPs). See ERPs
- Excitatory amino acids
glycinergic modulation of phencyclidine (PCP)-induced activity, 202
- F**
- [Fluorine-18]fluorodeoxyglucose (FDG)
dextroamphetamine effects on brain glucose metabolism, 370
- Fluoxetine
effects, 1
effects on sleep EEG, 241
- Fluphenazine
upregulation of D₂-like receptor subtypes, 186
- Fos
lithium effects, 12
- Frontal cortex
neuropeptide Y electrophysiologic actions, 34
risperidone effects, 44
- G**
- GABA_A-/benzodiazepine receptor
premenstrual syndrome, 370
- Geller, Edward
in memoriam, 350
- Genes
immediate early
amperozide effects, 197
lithium effects, 12
nicotine effects, 151
- Glucocorticoid receptor
menstrual cycle changes, 100
- Growth hormone
effects in depression and mania, 258
- H**
- Hippocampus
chronic amphetamine pretreatment effects, 130
- Homovanillic acid
schizophrenia, 316
- 5-HT₂
MDL 100,907 effects, 175
- 5-HT₂ receptors
depression, 341
- 5-HT_{1A} autoreceptors
sleep deprivation effects on serotonin, 72
- 5-HT_{2A} receptor genes
schizophrenia, 274
- 5-HT_{1A} receptors
divalproex sodium, 382
regulation of variants, 18
- 5-HT_{1D} receptor agonist
serotonergic function in depression or mania, 258
- L-5-HTP
fluoxetine effects, 1
- Human
corticotropin-releasing factor axon distribution across human brainstem nuclei, 325
dopamine D₂ receptor occupancy by exogenous dopamine, 162
positron emission tomography (PET) study of MDL 100,907, 175
- 5-Hydroxytryptamine. See 5-HT
- Hypothalamus
chronic amphetamine pretreatment effects, 130
- Hypothermia
ipsapirone, 382
- I**
- [¹²³I]IBZM
dopamine effects, 162
- Imaging
dextroamphetamine effects on brain glucose metabolism, 370
- Immediate early genes
amperozide effects, 197
lithium effects, 12
nicotine effects, 151
- Immunocytochemistry
corticotropin-releasing factor axon distribution across human brainstem nuclei, 325
- In vivo binding
dopamine D₂ receptor occupancy by exogenous dopamine, 162
- In vivo occupancy
nafadotride, 67
- Interleukin-2 receptors
IL-2 receptor-β cDNA clones, 57
- Ipsapirone
hypothermic, hormonal, and behavioral, 382
- J**
- Jun
lithium effects, 12
- Jun-B
nicotine effects, 151
- K**
- Ketamine
schizophrenia, 141
- Ketoconazole
effects on 5-HT_{1A} function, 246
- L**
- Ligands
neuropsychiatric disorders, 293
- Lithium
effects, 12
- Locomotor activity
chronic amphetamine pretreatment effects, 130
- Locus coeruleus
corticotropin-releasing factor axon distribution across human brainstem nuclei, 325
- Lymphocytes
glucocorticoid receptor effects, 100
- M**
- Major depressive episode
arginine vasopressin, 284
- Mania
sumatriptan effects on serotonergic function, 258
- MDL 100,907
positron emission tomography (PET) study, 175
- Menstrual cycle
glucocorticoid receptor effects, 100
- Microdialysis
chronic amphetamine pretreatment effects, 130
risperidone effects, 44
- Midazolam
premenstrual syndrome, 370
- Molecular cloning
IL-2 receptor-β cDNA clones, 57
- mRNA
menstrual cycle, 100
- N**
- N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinolone
nafadotride effects, 67
- N-methyl-D-aspartate (NMDA) receptors.
See NMDA receptors
- Nafadotride
effects on D₂ dopamine receptors, 67
- Negative symptoms
glycinergic modulation of phencyclidine (PCP)-induced activity, 202
- Nemonapride
effects on gene expression in rat forebrain, 27
upregulation of D₂-like receptor subtypes, 186
- Neuroleptic drugs
risperidone
effects on serotonin output, 44
- Neuropeptides
anxiety disorders, 360
neuropeptide Y electrophysiologic actions, 34
- Neuroplasticity
schizophrenia, 205
- Neuropsychiatric disorders
brain imaging, 293
- Neuroreceptors
neuropsychiatric disorders, 293
- Neuroticism
arginine vasopressin, 284
- Neurotransmitters
neuropsychiatric disorders, 293
- Nicotine
effects on Fos expression, 151
- NMDA receptors
glycinergic modulation of phencyclidine (PCP)-induced activity, 202
schizophrenia, 141
- Norepinephrine
chronic amphetamine pretreatment effects, 130
schizophrenia, 316
- Nucleus accumbens
amperozide effects, 197
nicotine effects, 151

O

- Obsessive compulsive disorder
 - fluoxetine effects, 1
- Oxytocin
 - conditioned place preference paradigm, 353
 - major depression, 284

P

- Pathophysiology
 - schizophrenia, 205
- Phencyclidine
 - effects, 82
 - prefrontal cortex function effects, 92
- Polymorphism
 - regulation of 5-HT_{1A} receptor variants, 18
 - schizophrenia, 274, 279
- Positron emission tomography (PET)
 - cocaine withdrawal and striatal 6-FDOPA uptake, 402
 - dextroamphetamine effects on brain glucose metabolism, 370
 - MDL 100,907, 175
 - neuropsychiatric disorders, 293
 - schizophrenia, 230
- Postmortem
 - corticotropin-releasing factor axon distribution across human brainstem nuclei, 325
- Prefrontal cortex
 - phencyclidine effects, 92
- Premenstrual syndrome
 - midazolam, 370
- Progesterone metabolites
 - premenstrual syndrome, 370
- Prolactin
 - fluoxetine effects, 1
- Promoter region
 - schizophrenia, 274
- Psychomimetics
 - phencyclidine, 92
- Psychomotor retardation
 - arginine vasopressin, 284
- Psychosis
 - ketamine effects, 141

R

- Raphe
 - corticotropin-releasing factor axon distribution across human brainstem nuclei, 325
- Rats
 - corticotropin-releasing factor localization, 307
 - oxytocin and conditioned place preference paradigm, 353
 - phencyclidine effects, 92
 - Y-43611 effects on forebrain, 27
- Receptor subtype
 - corticotropin-releasing factor localization in rat brain, 307

- Regional cerebral blood flow
 - antipsychotics effects, 230
- Reinforcing
 - conditioned place preference paradigm, 353
- Rodents
 - glycinergic modulation of phencyclidine (PCP)-induced activity, 202

S

- S[+]-N-n-propylnorapomorphine
 - upregulation of D₂-like receptor subtypes, 186
- Saccadic eye velocity
 - premenstrual syndrome, 370
- [¹²⁵I]Savagine
 - corticotropin-releasing factor localization in rat brain, 307
- Schizophrenia
 - adenosine A_{2A} agonists, 82
 - antipsychotics effects on regional cerebral blood flow, 230
 - clozapine, 316
 - dopamine effects, 162
 - glycinergic modulation of phencyclidine (PCP)-induced activity, 202
 - 5-HT_{2A} receptor gene, 274
 - pathophysiology, 205
 - phencyclidine effects, 92
 - trinucleotide repeat clones, 279
- Second messenger
 - protein kinase C (PKC) activation, 117
- Sedation
 - premenstrual syndrome, 370
- Serotonin
 - amperozide effects, 197
 - antiglucocorticoids effects, 246
 - anxiety disorders, 360
 - depression, 341
 - divalproex sodium, 381
 - fluoxetine effects, 1
 - protein kinase C (PKC) activation, 117
 - regulation of 5-HT_{1A} receptor variants, 18
 - risperidone effects, 44
 - sleep deprivation effects, 72
- Serotonin_{2A/2c}
 - protein kinase C (PKC) activation, 117
- Signal transduction
 - IL-2 receptor-β cDNA clones, 57
- Single photon emission computed tomography (PET)
 - neuropsychiatric disorders, 293
- Single-stranded conformation
 - polymorphism
 - schizophrenia, 274
- Sleep deprivation
 - effects on serotonin, 72
- Sleep EEG
 - fluoxetine effects, 241
- Spectral analysis
 - neuropeptide Y electrophysiologic actions, 34

- neuropeptide Y electrophysiologic actions, 34
- Spiperone
 - upregulation of D₂-like receptor subtypes, 186
- Stimulants
 - brain glucose metabolism, 370
 - cocaine withdrawal and striatal 6-FDOPA uptake, 402
- Stress
 - corticotropin-releasing factor localization in rat brain, 307
- Striatal 6-FDOPA uptake
 - cocaine withdrawal, 402
- Striatum
 - amperozide effects, 197
 - dopamine D₂ receptor occupancy by exogenous dopamine, 162
 - nafadotride effects, 67
- Sumatriptan
 - serotonergic function in depression or mania, 258
 - [³H]Spiperone nafadotride effects, 67
- Symptomatology
 - schizophrenia, 316

T

- Transporter
 - protein kinase C (PKC) activation, 117
- Tricyclic antidepressants
 - effects, 1
- Trinucleotide repeat clones
 - schizophrenia, 279
- Tryptophan
 - depression, 341

U

- Utilization
 - phencyclidine effects, 92

V

- Ventral mesencephalon
 - corticotropin-releasing factor axon distribution across human brainstem nuclei, 325

W

- Working memory
 - phencyclidine effects, 92

Y

- Y-43611
 - effects on gene expression in rat forebrain, 27